You just read:

IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations

News provided by

IDEAYA Biosciences, Inc.

Jul 11, 2019, 06:00 ET